Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20029849 | 0.81 | GSK3A (0.36) | TTRCES1KMT2AALDH1A1MEN1 | |
| SCHEMBL7756746 | 0.78 | TTR (0.52) | TTRCES1CASP3KMT2AALDH1A1 | |
| SCHEMBL15206754 | 0.77 | TTR (0.50) | TTRCES1CASP3KMT2AALDH1A1 | |
| SCHEMBL1137933 | 0.77 | TTR (0.55) | TTRCES1CASP3KMT2AALDH1A1 | |
| SCHEMBL21848273 | 0.77 | TTR (0.50) | TTRCES1CASP3KMT2AALDH1A1 | |
| SCHEMBL754994 | 0.77 | CES1 (0.50) | TTRCES1CASP3KMT2AALDH1A1 | |
| SCHEMBL21848225 | 0.74 | TTR (0.39) | TTRCES1CASP3CA2CA9 | |
| SCHEMBL1137970 | 0.74 | TTR (0.47) | TTRCES1KMT2AALDH1A1MEN1 | |
| SCHEMBL21848246 | 0.74 | TTR (0.39) | TTRCES1CASP3CA2CA9 | |
| SCHEMBL30067921 | 0.74 | TTR (0.47) | TTRCES1KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-04-10 | — | — | US | disclosed |
| WO-2025049994-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-106749295-B | A kind of synthetic method of loop coil Oxoindole gamma-butyrolacton class compound | 中国药科大学 | 2019-04-12 | — | — | CN | disclosed |
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| EP-3262041-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2018-01-03 | — | — | EP | disclosed |
| CN-105732476-B | A kind of carbazole isatin type compound and its preparation method and purposes | 吉首大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-104829608-B | A kind of cumarin thiazole indolone type compound and its preparation method and purposes | 吉首大学 | 2017-06-30 | — | — | CN | disclosed |
| CN-106749295-A | A kind of synthetic method of volution Oxoindole gamma-butyrolacton class compound | 中国药科大学 | 2017-05-31 | — | — | CN | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | disclosed |
| EP-2163554-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-03-17 | — | — | EP | disclosed |
| EP-1814881-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| WO-2006044415-A2 | CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112935-B2 | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, CIT | TTR 4448/4885CES1 2547/4885CASP3 3745/4885 |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | TTR 4346/4885CES1 1348/4885CASP3 4351/4885 |
| US-20250114345-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | EP300, CREBBP, HDAC1 | TTR 1354/4885CES1 209/4885CASP3 3804/4885 |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGDR | TTR 4065/4885CES1 475/4885CASP3 1373/4885 |
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | TTR 4448/4885CES1 2547/4885CASP3 3745/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | TTR 400/4885CES1 3034/4885CASP3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.